MedChemComm p. 593 - 598 (2017)
Update date:2022-08-04
Topics:
Davis, Rachel E.
Zhang, Zheng
Blagg, Brian S. J.
Inhibition of the Hsp90 C-terminus is an attractive therapeutic paradigm for the treatment of cancer, however the developmental space of C-terminal inhibitors is limited. It was hypothesized that the combination of two previously identified scaffolds into a single structure could provide a platform for which to probe the three-dimensional space within the Hsp90 C-terminal binding pocket. The resulting chimeric compounds displayed anti-proliferative activity at low micromolar concentrations and manifested inhibitory activity in an Hsp90-dependent rematuration assay. Initial structure-activity relationships suggest that this new scaffold binds Hsp90 in a conformation different from that of the parent compounds, and consequently, provides a new opportunity to develop more efficacious inhibitors of the Hsp90 C-terminal binding pocket.
View MoreContact:86-21-57725962
Address:shanghai
Zhonghao (dalian) Research and Design Institute of Chemical Industry Co., Ltd
Contact:+86 411 84674606
Address:201, Huangpu Road , Shahekou District, Dalian ,116023-China
Shanghai Mokai Pharmaceutical Co.,Ltd
Contact:021-60257269
Address:Rm506,No.915,Zhenbei Road,Shanghai,200333,China
Wuhan Sunrise Pharmaceutical Technology Co., Ltd
Contact:+86-27-83314682
Address:Room 340, New material Industrial base No.17, Gu Tian Five Lu , Qiaokou District, Wuhan , China
Contact:Tel: +86-25-58353800
Address:23 Lijing Road, Nanjing Hi-Tech Zone, Nanjing, Jiangsu, China, 210061
Doi:10.1021/ol006988j
(2001)Doi:10.1021/jo00969a006
(1972)Doi:10.1021/ol006751n
(2001)Doi:10.1039/b000568l
(2000)Doi:10.1021/acscatal.7b01543
(2017)Doi:10.1016/0045-6535(94)90282-8
(1994)